Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCUL201
- Development stage
- Preclinical
- Lead developer
- Shenzhen Oculgen Biomedical Technology
- Administration
- Ophthalmic
01
Overview
OCUL201 is a preclinical-stage drug candidate developed by Shenzhen Oculgen Biomedical Technology for the treatment of retinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). It is characterized as a multi-target therapeutic program, suggesting it is designed to inhibit multiple biological pathways involved in the progression of ocular diseases, such as angiogenesis and inflammation. While the specific molecular targets and modality (e.g., small molecule or biologic) have not been publicly disclosed by the developer, the program aims to address unmet needs in retinal health through a multi-pathway approach.
Beyond the preview
Go deeper on OCUL201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCUL201.